Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adult Subjects With Congenital Adrenal Hyperplasia

Trial Profile

A Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adult Subjects With Congenital Adrenal Hyperplasia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crinecerfont (Primary)
  • Indications Congenital adrenal hyperplasia
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CAHlibrate
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 12 May 2023 Results of post-hoc analysis assessing baseline hormone levels and glucocorticoid (GC) doses correlated with treatment response will be presented at ECE 2023, the 25th European Congress of Endocrinology in Istanbul, Turkey from May 13-16.
    • 12 May 2023 Results presented in a Neurocrine Biosciences Media Release.
    • 15 Oct 2021 Results assessing safety, tolerability, and efficacy of crinecerfont published in the Journal of Clinical Endocrinology and Metabolism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top